MedTrace Logo

Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

NCT04748939 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-08-06

No results posted yet for this study

Summary

A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

recombinant subunit herpes zoster vaccine

vaccine administration

Sponsors & Collaborators

  • Tuen Mun Hospital

    lead OTHER_GOV

Principal Investigators

  • Chi Chiu Mok · Tuen Mun Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2025-12-31
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04748939 on ClinicalTrials.gov